News coverage about Trupanion (NASDAQ:TRUP) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Trupanion earned a news sentiment score of 0.05 on Accern’s scale. Accern also gave media headlines about the financial services provider an impact score of 44.5404922708654 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Trupanion, Inc. (TRUP) Insider Sells $105,350.00 in Stock (americanbankingnews.com)
- Trupanion (TRUP): Canaccord Raises PT $5 After Management Meetings – StreetInsider.com (streetinsider.com)
- Trupanion, Inc. (TRUP) Receives Consensus Rating of “Buy” from Analysts (americanbankingnews.com)
- Trupanion (TRUP) Stock Rating Upgraded by BidaskClub (americanbankingnews.com)
- Medical insurance for pets helps give pet owners peace of mind during the holidays (finance.yahoo.com)
A number of equities analysts have recently commented on TRUP shares. BidaskClub lowered shares of Trupanion from a “hold” rating to a “sell” rating in a report on Thursday, September 7th. CL King began coverage on shares of Trupanion in a report on Tuesday, November 21st. They set a “neutral” rating on the stock. Zacks Investment Research raised shares of Trupanion from a “hold” rating to a “buy” rating and set a $29.00 target price on the stock in a report on Wednesday, October 4th. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $35.00 target price (up previously from $29.00) on shares of Trupanion in a report on Tuesday, October 31st. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $28.83.
Trupanion (NASDAQ:TRUP) last announced its quarterly earnings results on Thursday, November 2nd. The financial services provider reported $0.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.04. The business had revenue of $63.12 million for the quarter, compared to analyst estimates of $61.44 million. Trupanion had a negative net margin of 1.05% and a negative return on equity of 7.41%. The company’s revenue was up 30.5% on a year-over-year basis. During the same quarter last year, the firm earned ($0.06) EPS. equities research analysts forecast that Trupanion will post -0.04 earnings per share for the current year.
In other news, insider Asher Bearman sold 4,039 shares of the firm’s stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $28.40, for a total value of $114,707.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Darryl Rawlings sold 3,500 shares of the firm’s stock in a transaction dated Wednesday, December 13th. The stock was sold at an average price of $30.10, for a total transaction of $105,350.00. Following the completion of the sale, the insider now directly owns 1,393,476 shares of the company’s stock, valued at $41,943,627.60. The disclosure for this sale can be found here. In the last three months, insiders sold 122,039 shares of company stock worth $3,229,133. Insiders own 31.24% of the company’s stock.
Trupanion, Inc provides medical insurance plans for cats and dogs throughout the United States, Canada and Puerto Rico. The Company operates in two business segments: subscription business and other business. The subscription business segment includes monthly subscriptions for its medical plan, which are marketed to consumers.
Receive News & Ratings for Trupanion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trupanion and related companies with MarketBeat.com's FREE daily email newsletter.